Form 4: UroGen Pharma Director Converts RSUs to Shares

Sentiment:

Insider Transaction Report 27 February 2026 4:44 PM

UroGen Pharma Ltd. Director James A. Robinson Jr. converted 2,000 restricted stock units into ordinary shares, increasing his direct beneficial ownership to 4,000 shares.

Delay expectedThe transaction occurred on February 26, 2025, but the filing was signed on February 27, 2026, indicating a delay of over one year in reporting the change in beneficial ownership. Additionally, the 'Date of Earliest Transaction' is listed as February 26, 2026, which is after the actual transaction date and the signature date, suggesting a potential discrepancy or further delay.

Summary

James A. Robinson Jr., a Director of UroGen Pharma Ltd. (URGN), reported a change in his beneficial ownership.
On February 26, 2025, Mr. Robinson acquired 2,000 ordinary shares through the conversion of Restricted Stock Units (RSUs).
Each RSU represents a contingent right to receive one ordinary share of the Issuer.
Following this transaction, Mr. Robinson directly beneficially owns 4,000 ordinary shares.
The filing indicates an 'Earliest Transaction Date' of February 26, 2026, and was signed on February 27, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, as a director increasing their direct shareholding, even through RSU conversion, can indicate confidence in the company's future, despite the noted filing delay.

Positives

Director James A. Robinson Jr. increased his direct beneficial ownership of UroGen Pharma Ltd. ordinary shares by 2,000, now holding a total of 4,000 shares, which can signal confidence in the company.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that insider transactions, such as the conversion of Restricted Stock Units (RSUs) into ordinary shares, are routine events for directors and executives. These transactions typically reflect the execution of pre-established compensation plans and are a common mechanism for insiders to realize equity compensation.

Comparison to Industry Standards

NA This Form 4 filing reports a routine insider transaction (RSU conversion) and does not contain financial or operational results that can be directly compared to industry benchmarks or specific competitor projects.

Related Party Transactions

The conversion of Restricted Stock Units (RSUs) into ordinary shares by a director is a form of compensation and is considered a related party transaction in the context of executive compensation.

Stakeholder Impact

Shareholders may view the increase in a director's direct shareholding as a minor positive indicator of insider confidence in the company's long-term prospects.

Key Dates

Date	Description
02/26/2025	Transaction Date for the conversion of Restricted Stock Units into ordinary shares.
02/26/2026	Date of Earliest Transaction, as stated in the filing.
02/27/2026	Signature date of the reporting person's attorney-in-fact, indicating the filing date.

Keywords

UroGen Pharma, URGN, Form 4, insider transaction, beneficial ownership, restricted stock units, RSU, director, equity

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.